RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stockseems to me the agreement specifically states that licensee (adlai) and oncolytics are BOTH contract manufacturers.
both adlai and oncolytics can subcontract with third parties (subject to joint approval) for the production of reolysin. for all we know, this may have already happened and been shielded by the confidentiality provisions.
regardless, if/when adlai obtains approval to market in its exclusive territory ((china (prc), hong kong, macau, republic of sinapore, korea and taiwan)) it's quite possible oncy's current manufacturer would not be able to meet the needs of adlai, especially if oncy were to simultaneously obtains marketing approvals for the u.s. or any of the rest of the world not exclusively ceeded to adlai.
consider the fact that pfizer's covid-19 vaccine, as of the beginning of this year, was being manufactured among 11 sites across five countries, including the u.s., germany, belgium, ireland, and croatia and they engage more than 20 suppliers.
seems like the agreement(s) were trying to anticipate and provide for the situation in which milliporesigma could not meet adlai's future demand much less what could be a worldwide demand.